Establishment Labs (ESTA) Projected to Announce Quarterly Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is projected to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Establishment Labs to post earnings of ($0.2568) per share and revenue of $66.81 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The company’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.57) EPS. On average, analysts expect Establishment Labs to post ($1.08) EPS for the current fiscal year and ($0.01) EPS for the next fiscal year.

Establishment Labs Price Performance

Shares of ESTA opened at $62.28 on Thursday. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -47.54 and a beta of 1.06. The stock has a 50 day moving average of $68.43 and a 200-day moving average of $74.56. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11. Establishment Labs has a 52 week low of $47.00 and a 52 week high of $97.59.

Wall Street Analysts Forecast Growth

ESTA has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $85.00 price objective on Establishment Labs and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Mizuho boosted their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. TD Cowen reiterated a “buy” rating and set a $117.00 target price on shares of Establishment Labs in a research note on Thursday, October 15th. Finally, Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Thursday, August 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.56.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.